NO983002D0 - Vitronectin receptor antagonists - Google Patents

Vitronectin receptor antagonists

Info

Publication number
NO983002D0
NO983002D0 NO983002A NO983002A NO983002D0 NO 983002 D0 NO983002 D0 NO 983002D0 NO 983002 A NO983002 A NO 983002A NO 983002 A NO983002 A NO 983002A NO 983002 D0 NO983002 D0 NO 983002D0
Authority
NO
Norway
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
NO983002A
Other languages
Norwegian (no)
Other versions
NO983002L (en
Inventor
Fadia E Ali
William E Bondinell
Richard M Keenan
Thomas W Ku
William H Miller
James Samanen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO983002D0 publication Critical patent/NO983002D0/en
Publication of NO983002L publication Critical patent/NO983002L/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
NO983002A 1995-12-29 1998-06-26 Vitronectin receptor antagonists NO983002L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US953295P 1995-12-29 1995-12-29
PCT/US1996/020744 WO1997024122A1 (en) 1995-12-29 1996-12-20 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
NO983002D0 true NO983002D0 (en) 1998-06-26
NO983002L NO983002L (en) 1998-08-26

Family

ID=21738237

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983002A NO983002L (en) 1995-12-29 1998-06-26 Vitronectin receptor antagonists

Country Status (16)

Country Link
EP (1) EP0895475A4 (en)
JP (1) JP2000502708A (en)
KR (1) KR19990076876A (en)
CN (1) CN1209060A (en)
AU (1) AU1353897A (en)
BR (1) BR9612378A (en)
CA (1) CA2241724A1 (en)
CZ (1) CZ203798A3 (en)
HU (1) HUP9901116A2 (en)
IL (1) IL125034A0 (en)
MX (1) MX9805253A (en)
NO (1) NO983002L (en)
PL (1) PL327919A1 (en)
TR (1) TR199801255T2 (en)
WO (1) WO1997024122A1 (en)
ZA (1) ZA9610855B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0777657A1 (en) * 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
WO1997026250A1 (en) * 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
DE69716900T2 (en) * 1996-04-10 2003-07-03 Merck & Co Inc Alpha v Beta 3 ANTAGONISTS
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
DE19653645A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
CA2297910A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
WO1999030709A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
ID26223A (en) * 1998-03-10 2000-12-07 Smithkline Beecham Corp VITRONEKTIN RECEPTOR ANTAGONISTS
CA2326045C (en) * 1998-04-01 2008-12-09 Janssen Pharmaceutica N.V. Pde iv inhibiting pyridine derivatives
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
SE9803518D0 (en) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
CA2358855A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
JP2003505416A (en) 1999-07-21 2003-02-12 ワイス Bicyclic antagonist selective for αvβ3 integrin
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
DE10028575A1 (en) 2000-06-14 2002-03-14 Basf Ag integrin
FR2800067B1 (en) * 1999-10-21 2004-12-17 Rhodia Chimie Sa INTERMEDIATES FOR THE MANUFACTURE OF A BENZOFURANE OR NITROGEN BENZOTHIOPHENE DERIVATIVE IN POSITION 5 AND THEIR USES
FR2820743B1 (en) 2001-02-09 2005-02-25 Pf Medicament SYNTHESIS METHOD AND INTERMEDIARIES FOR THE PREPARATION OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
EP1678168B1 (en) * 2003-10-24 2012-07-11 Exelixis, Inc. P70s6 kinase modulators and method of use
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006041046A1 (en) * 2004-10-13 2006-04-20 Sankyo Company, Limited Pyridine derivative
US7262210B2 (en) 2005-04-20 2007-08-28 Janssen Pharmaceutica N.V. Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
AR060901A1 (en) * 2006-05-12 2008-07-23 Jerini Ag HETEROCICLICAL COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE
EP2441464B1 (en) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
JP2012527474A (en) 2009-05-22 2012-11-08 エクセリクシス, インク. Benzoxazepine-based PI3K / MT0R inhibitors for proliferative diseases
EP2445534A2 (en) 2009-05-25 2012-05-02 Merck Patent GmbH Continuous administration of cilengitide in cancer treatments
WO2011082967A1 (en) * 2009-12-17 2011-07-14 Basf Se Method for producing higher ethanolamines
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CA2950390C (en) 2014-05-30 2020-09-22 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
EP3468953A1 (en) 2016-06-13 2019-04-17 GlaxoSmithKline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1
EP4147698A1 (en) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
RU2022108080A (en) * 2017-02-28 2022-04-07 Морфик Терапьютик, Инк. INTEGRIN AVB6 INHIBITORS
TW202035400A (en) 2018-08-29 2020-10-01 美商莫菲克醫療股份有限公司 Inhibiting αvβ6 integrin
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627754A (en) * 1970-05-13 1971-12-14 Hoffmann La Roche Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts
EP0593603B1 (en) * 1991-06-28 2002-11-20 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
CN1041921C (en) * 1992-12-21 1999-02-03 史密丝克莱恩比彻姆公司 Bicyclic fibrinogen antagonists
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vitronectin receptor antagonists
ZA9610853B (en) * 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
KR19990076877A (en) * 1995-12-29 1999-10-25 스티븐 베네티아너 Bitronectin receptor antagonist

Also Published As

Publication number Publication date
CN1209060A (en) 1999-02-24
HUP9901116A2 (en) 2000-03-28
ZA9610855B (en) 1997-11-24
EP0895475A1 (en) 1999-02-10
EP0895475A4 (en) 2000-08-23
CA2241724A1 (en) 1997-07-10
BR9612378A (en) 1999-07-13
PL327919A1 (en) 1999-01-04
MX9805253A (en) 1998-10-31
TR199801255T2 (en) 1998-10-21
NO983002L (en) 1998-08-26
AU1353897A (en) 1997-07-28
WO1997024122A1 (en) 1997-07-10
KR19990076876A (en) 1999-10-25
JP2000502708A (en) 2000-03-07
IL125034A0 (en) 1999-01-26
CZ203798A3 (en) 1998-12-16

Similar Documents

Publication Publication Date Title
BR9612381A (en) Vitronectin receptor antagonists
NO983003D0 (en) Vitronectin receptor antagonists
NO983002D0 (en) Vitronectin receptor antagonists
NO965608D0 (en) Vitronectin receptor antagonists
NO972016D0 (en) Indolyl-Y receptor antagonists
DK0957917T3 (en) vitronectin receptor antagonists
NO983737D0 (en) IL-8 receptor antagonists
NO993350D0 (en) Vitronectin receptor antagonists
FI960953A (en) endothelin receptor antagonists
DE69812096T2 (en) NEUROPEPTID Y RECEPTOR ANTAGONISTS
ID16742A (en) ENDOTELIN RECEPTOR ANTAGONISTS
ATE258548T1 (en) ADHESION RECEPTOR ANTAGONISTS
NO20001514D0 (en) Vitronectin receptor antagonist
NO20001407D0 (en) Vitronectin receptor antagonists
ID24726A (en) TROMBIN RECEPTOR ANTAGONISTS
NO20001515D0 (en) Vitronectin receptor antagonist
NO20004503L (en) Vitronectin receptor antagonists
BR9507220A (en) Endothelin receptor antagonists
DZ2322A1 (en) Vitronectin receptor antagonists.
ATE341324T1 (en) ENDOTHELIN RECEPTOR ANTAGONISTS
DE69616364D1 (en) ENDOTHELINE RECEPTOR ANTAGONISTS
NO20010620D0 (en) Vitronectin receptor antagonists
BR9603432A (en) Endothelin receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application